Wells Fargo Maintains Equal-Weight on ResMed, Raises Price Target to $250
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Wells Fargo analyst Nathan Treybeck maintains ResMed (NYSE:RMD) with a Equal-Weight and raises the price target from $215 to $250.
Wells Fargo analyst Nathan Treybeck maintains ResMed (NYSE:RMD) with a Equal-Weight and raises the price target from $215 to $250.